Newsmeme!
Discover News you didn't know existed
Sinus Rhythm
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Multaq approved for atrial fibrillation by FDA
Published July 7, 2009, 7:18 pm, News-Medical-Net
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular ...
Sorin Group Announces World's Smallest Implantable Dual Chamber Pacemaker Now Available in Canada
Published July 7, 2009, 6:59 am, Business Wire via Yahoo! Finance
TORONTO----Sorin Group, , a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the Health Canada Therapeutic Products Directorate approval to market the REPLY™ family of dual and single chamber rate adaptive pacemakers.
FDA Approves Multaq For Patients With Atrial Fibrillation Or Atrial Flutter
Published July 7, 2009, 1:24 am, PharmaceuticalOnline
Sanofi-aventis announced recently that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets.
Sorin Group Announces Regulatory Approval And First Implants Of New-Platform FACIL And REPLY Pacemakers In Japan
Published July 6, 2009, 6:36 am, Medical News Today
Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced the Ministry of Health, Labor and Welfare (MHLW) approval to market the FACIL™ and REPLY™ families of dual and single chamber rate responsive pacemakers.
FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter
Published July 3, 2009, 5:07 am, Medical News Today
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease.
*vwd/BUSINESS WIRE: Sorin Group Announces Regulatory Approval and First Implants of New-Platform FACIL and REPLY ...
Published July 2, 2009, 10:48 pm, vwd.de
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
Sanofi-aventis' Multaq receives US FDA nod to treat patients with atrial fibrillation or atrial flutter
Published July 2, 2009, 10:48 pm, PharmaBiz
Sanofi-aventis announced that the US Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg tablets.
Sorin Group Announces Regulatory Approval and First Implants of New-Platform FACIL and REPLY Pacemakers in Japan
Published July 2, 2009, 10:30 pm, Business Wire via Yahoo! Finance
TOKYO----Sorin Group, , a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the Ministry of Health, Labor and Welfare approval to market the FACIL™ and REPLY™ families of dual and single chamber rate responsive pacemakers.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |